A phase I/II clinical trial of immunotherapy with humanized MN-14 IgG [labetuzumab] in recurrent, metastatic, unresectable colorectal and breast carcinomas
Phase of Trial: Phase I/II
Latest Information Update: 21 Oct 2005
At a glance
- Drugs Labetuzumab (Primary)
- Indications Advanced breast cancer; Colorectal cancer
- Focus Adverse reactions
- 10 Sep 2005 New trial record.